US FDA Approves Extavia - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with This Devastating Disease

US FDA Approves Extavia - the First in a New Portfolio of Planned MS
Therapies from Novartis to Help Patients with This Devastating Disease
August 17, 2009
Basel, August 17, 2009 - The US Food and Drug Administration (FDA) has
approved Extavia (interferon beta-1b), the first in a new planned
portfolio of multiple sclerosis (MS) medicines from Novartis to help
patients manage this devastating disease. Extavia is approved by the
FDA for the treatment of relapsing forms of MS to reduce the frequency
of clinical exacerbations. The therapy is also indicated for patients
who have experienced a first clinical episode of MS...